Protective function of pyridoxamine on retinal photoreceptor cells via activation of the p-Erk1/2/Nrf2/Trx/ASK1 signalling pathway in diabetic mice

Molecular Medicine Reports

Volumn 14, Issue 1, 2016, Pages 420-424

  Ren, Xiang ^a   Sun, Hong ^a   Zhang, Chenghong ^a   Li, Chen ^a,b   Wang, Jinlei ^a   Shen, Jie ^a   Yu, Dong ^a   Kong, Li ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b Department of Internal Medicine   (China)

Author keywords

Apoptosis; Diabetic retinopathy; Pyridoxamine; Thioredoxin

Indexed keywords

APOPTOSIS SIGNAL REGULATING KINASE 1; EOSIN; HEMATOXYLIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PYRIDOXAMINE; STREPTOZOCIN; THIOREDOXIN; THIOREDOXIN REDUCTASE; TRANSCRIPTION FACTOR NRF2; PROTECTIVE AGENT; TXN1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL COUNT; CELL DAMAGE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES CONTROL; ENZYME ACTIVATION; EYE PROTECTION; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; LIGHT DAMAGE; LIGHT INDUCED RETINAL PHOTORECEPTOR CELL DAMAGE; LIPID DIET; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHOTORECEPTOR CELL; PROTEIN EXPRESSION; RETINA CELL; RETINA INJURY; RETINAL OUTER NUCLEAR LAYER; SIGNAL TRANSDUCTION; STAINING; UPREGULATION; WESTERN BLOTTING; ANIMAL; DIABETIC RETINOPATHY; DISEASE MODEL; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; INSULIN RESISTANCE; METABOLISM; PATHOLOGY; RADIATION RESPONSE;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; INSULIN RESISTANCE; MALE; MAP KINASE KINASE KINASE 5; MAP KINASE SIGNALING SYSTEM; MICE; NF-E2-RELATED FACTOR 2; PHOTORECEPTOR CELLS, VERTEBRATE; PROTECTIVE AGENTS; PYRIDOXAMINE; SIGNAL TRANSDUCTION; THIOREDOXINS;

EID: 84973446489     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2016.5270     Document Type: Article

References (17)

1. Stitt AW, Lois N, Medina RJ, Adamson P and Curtis TM: Advances in our understanding of diabetic retinopathy. Clin Sci (Lond) 125: 1-17, 2013.
2. Tarr JM, Kaul K, Chopra M, Kohner EM and Chibber R: Pathophysiology of diabetic retinopathy. ISRN Ophthalmol 2013: 343560, 2013.
3. Brownlee M: The pathobiology of diabetic complications: A unifying mechanism. Diabetes 54: 1615-1625, 2005.
4. Laurent TC, Moore EC and Reichard P: Enzymatic synthesis of deoxyribonucleotides. Iv. Isolation and characterization of thioredoxin, the hydrogen donor from Escherichia coli B. J Biol Chem 239: 3436-3444, 1964.
5. Johnson J, Maher P and Hanneken A: The flavonoid, eriodictyol, induces long-term protection in ARPE-19 cells through its effects on Nrf2 activation and phase 2 gene expression. Invest Ophthalmol Vis Sci 50: 2398-2406, 2009.
6. Turgut F and Bolton WK: Potential new therapeutic agents for diabetic kidney disease. Am J Kidney Dis 55: 928-940, 2010.
7. Voziyan PA, Metz TO, Baynes JW and Hudson BG: A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J Biol Chem 277: 3397-3403, 2002.
8. Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ and McGill JB: Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol 27: 605-614, 2007.
9. Ruta LM, Magliano DJ, Lemesurier R, Taylor HR, Zimmet PZ and Shaw JE: Prevalence of diabetic retinopathy in Type 2 diabetes in developing and developed countries. Diabetic Med 30: 387-398, 2013.
10. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-Ct method. Methods 25: 402-408, 2001.
11. Organisciak DT, Darrow RM, Barsalou L, Darrow RA, Kutty RK, Kutty G and Wiggert B: Light history and age-related changes in retinal light damage. Invest Ophthalmol Vis Sci 39: 1107-1116, 1998.
12. Jain SK and Lim G: Pyridoxine and pyridoxamine inhibits superoxide radicals and prevents lipid peroxidation, protein glycosylation, and (Na+ + K+)-ATPase activity reduction in high glucose-treated human erythrocytes. Free Radic Biol Med 30: 232-237, 2001.
13. Marcucci R, Zanazzi M, Bertoni E, Rosati A, Fedi S, Lenti M, Prisco D, Castellani S, Abbate R and Salvadori M: Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients. Transplantation 75: 1551-1555, 2003
14. Seger R and Krebs EG: The MAPK signaling cascade. FASEB J 9: 726-735, 1995.
15. Raman M, Chen W and Cobb MH: Differential regulation and properties of MAPKs. Oncogene 26: 3100-3112, 2007.
16. Zhang W and Liu HT: MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 12: 9-18, 2002.
17. Tan Y, Ichikawa T, Li J, Si Q, Yang H, Chen X, Goldblatt CS, Meyer CJ, Li X, Cai L and Cui T: Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo. Diabetes 60: 625-633, 2011.